CBDM.T, The Market and Business Intelligence Company Reviews The Vacc...( According to...)

According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.

Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.

According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.

In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).

Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total
'/>"/>